Results 31 to 40 of about 53,280 (246)

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial

Rheumatology and Therapy, 2023
Introduction This post hoc analysis of phase 2 trial data assessed the efficacy of tofacitinib on magnetic resonance imaging (MRI) outcomes with the detailed anatomy-based Canada–Denmark (CANDEN) MRI scoring system and evaluated tofacitinib suppression ...
Mikkel Østergaard, Joseph Wu, Lara Fallon, Sarah P. Sherlock, Cunshan Wang, Dona Fleishaker, Keith S. Kanik, Walter P. Maksymowych   +7 more
doaj   +1 more source

Tofacitinib Decreases Autophagy of Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients

Frontiers in Pharmacology, 2022
The pathway of Janus tyrosine kinases (JAKs) has a central role in the pathogenesis of Rheumatoid Arthritis (RA) by regulating multiple immune functions and cytokine production.
M. Vomero, M. Vomero, M. Caliste, C. Barbati, M. Speziali, A. I. Celia, F. Ucci, C. Ciancarella, E. Putro, T. Colasanti, G. Buoncuore, E. Corsiero, M. Bombardieri, F. R. Spinelli, F. Ceccarelli, F. Conti, C. Alessandri   +16 more
doaj   +1 more source

Alopecia areata: a multifactorial autoimmune condition [PDF]

, 2019
Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P., Henriquez, Fiona L., Reid, Stuart, Simakou, Teontor   +3 more
core   +1 more source

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

Therapeutic Advances in Gastroenterology, 2021
Introduction: Extraintestinal manifestations (EIMs) in patients with ulcerative colitis (UC) are common. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. We evaluated the efficacy of tofacitinib in patients with EIMs,
David T. Rubin, Walter Reinisch, Thomas Greuter, Paulo G. Kotze, Marcia Pinheiro, Rajiv Mundayat, Eric Maller, Marc Fellmann, Nervin Lawendy, Irene Modesto, Stephan R. Vavricka, Gary R. Lichtenstein   +11 more
doaj   +1 more source

Quantitative Muscle Magnetic Resonance Imaging Demonstrates Resolution of Muscle Edema in Refractory Dermatomyositis: A Post Hoc Analysis of a Proof-of-Concept Clinical Trial of Tofacitinib. [PDF]

ACR Open Rheumatol
Objective To evaluate changes in muscle edema using short‐tau inversion recovery (STIR) imaging and quantitative diffusion‐weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping in patients with refractory dermatomyositis (DM) treated with tofacitinib. Methods This post hoc imaging analysis included patients from a 12‐week, open‐label
Dabiri M, Nallapati A, Groener M, Debs P, Albayda J, Tiniakou E, Christopher-Stine L, Fayad L, Paik JJ.   +8 more
europepmc   +2 more sources

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

ACR Open Rheumatology, 2020
Objective Metabolic syndrome (MetS) is a cluster of concurrent risk factors for cardiovascular disease and type 2 diabetes. This post hoc analysis explored key efficacy and safety endpoints in patients with psoriatic arthritis (PsA) and MetS treated with
Christopher T. Ritchlin, Jon T. Giles, Alexis Ogdie, Juan J. Gomez‐Reino, Philip Helliwell, Pamela Young, Cunshan Wang, Joseph Wu, Ana Belén Romero, John Woolcott, Lori Stockert   +10 more
doaj   +1 more source

Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes [PDF]

, 2015
BACKGROUND: Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC).
Andrew G Bushmakin, Carla Mamolo, Chinyu Su, Joseph C Cappelleri, Julián Panés, Paul Healey   +5 more
core   +1 more source

Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis

Journal of International Medical Research, 2019
Background Tofacitinib is an oral Janus kinase (JAK) inhibitor that targets JAK1 and JAK3, and thus regulates immune response. Therefore, tofacitinib is used to treat immune-mediated inflammatory diseases such as chronic plaque psoriasis.
Fangyuan Tian, Zhaoyan Chen, Ting Xu
doaj   +1 more source

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

ACR Open Rheumatology, 2019
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis evaluated tofacitinib persistence in patients with RA in long‐term extension (LTE) studies up to 9.5 years.
Janet E. Pope, Edward Keystone, Shahin Jamal, Lisy Wang, Lara Fallon, John Woolcott, Irina Lazariciu, Douglass Chapman, Boulos Haraoui   +8 more
doaj   +1 more source